Frailty check could personalize bladder cancer care for seniors
NCT ID NCT06138561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a short survey called the Geriatric-8 can help doctors choose the best treatment for older patients with advanced bladder cancer who cannot take the strong chemotherapy drug cisplatin. Researchers will compare quality of life and side effects between two treatment approaches: one using a milder chemo followed by immunotherapy, and another using a newer drug combo. The goal is to find out which treatment works better for frail or at-risk patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Geriatric-8 survey (a frailty screening tool)
What this could lead to
If successful, this could help doctors personalize treatment decisions for older bladder cancer patients, improving quality of life and reducing side effects.
What could go wrong
This is an observational study that does not test a new drug, so it will not directly lead to a cure or new treatment. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact